Knight Therapeutics commits $10 mln to VCAP-backed HarbourVest fund
Canadian specialty pharmaceutical company Knight Therapeutics Inc (TSX: GUD) has committed $10 million to HarbourVest Canada Growth Fund LP, which is managed by U.S. private markets investor HarbourVest Partners. As reported by peHUB Canada in January, the HarbourVest vehicle is the fourth Canadian fund of funds affiliated with Ottawa's $400 million Venture Capital Action Plan. It is expected to raise about $300 million in total. The commitment from Knight Therapeutics is HarbourVest's first disclosed to date. Knight Therapeutics also invested in Teralys Capital Innovation Fund, which raised an initial $279 million last November.
6 April 2015•3 mins read
